Kamal Azzaoui

发表

Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis

Bin Chen, Andreas Bender, Meir Glick, 2009, J. Chem. Inf. Model..

19F NMR‐Based Fragment Screening for 14 Different Biologically Active RNAs and 10 DNA and Protein Counter‐Screens

H. Schwalbe, K. Azzaoui, B. Fürtig, 2020, Chembiochem : a European journal of chemical biology.

New Methods for Ligand-Based Virtual Screening: Use of Data Fusion and Machine Learning to Enhance the Effectiveness of Similarity Searching

Jérôme Hert, Peter Willett, David J Wilton, 2006, J. Chem. Inf. Model..

Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures.

P. Willett, J. Hert, E. Jacoby, 2004, Organic & biomolecular chemistry.

Knowledge‐Based and Computational Approaches to In Vitro Safety Pharmacology

Andreas Bender, Jeremy L. Jenkins, Kamal Azzaoui, 2009 .

NMR quality control of fragment libraries for screening

P. Schmieder, H. Schwalbe, K. Azzaoui, 2020, Journal of biomolecular NMR.

High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis

D. Bojanic, K. Azzaoui, S. Whitebread, 2006, Expert opinion on drug metabolism & toxicology.

Exploring the Druggability of Conserved RNA Regulatory Elements in the SARS‐CoV‐2 Genome

H. Schwalbe, K. Azzaoui, U. Scheffer, 2021, Angewandte Chemie.

Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures

Jérôme Hert, Peter Willett, Pierre Acklin, 2004, J. Chem. Inf. Model..

Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data

A. Bender, J. Jenkins, E. Jacoby, 2007, ChemMedChem.

Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection.

Peter Meier, Pierre Acklin, Kamal Azzaoui, 2005, Current topics in medicinal chemistry.